Application of Recombinant Antigens for the Diagnosis of Acute Epstein-Barr Virus Infection

  • Walter Hinderer
  • Günter Siegl
Part of the Applied Virology Research book series (AVIR, volume 3)


Primary infection with Epstein-Barr virus (EBV) can manifest as infectious mononucleosis (= mononucleosis infectiosa, morbus Pfeiffer, kissing disease, glandular fever) and can present with fever, pharyngitis, tonsillitis, lymphadenopathy, malaise, headache, myalgia, spleno- and hepatomegaly, rash, and leucocytosis. During childhood an EBV primary infection is mostly a mild or asymptomatic event, but even in adults severe complications are rarely observed. In the course of primary infection B-lymphocytes as well as oropharyngeal and probably also nasopharyngeal and salivary epithelial cells will be infected, and virus may persist in such cells for the entire life of the individual. Approximately 90% of the human population is infected and is thus capable of transmitting the virus for life. In general, the transmission does not occur by flighty contacts, but needs a close connexion of oral surfaces, e. g. during kissing (for reviews see Cheeseman, 1988 and Sumaya, 1989).


Infectious Mononucleosis Recombinant Antigen Western Blot Experiment Early Antigen Virus Capsid Antigen 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Baboonian, C., Halliday, D., Venables, P. J. W., Pawlowski, T., Millman, G. and Maini, R. N. (1989). Rheumatol. Intl. 9, 161–166.Google Scholar
  2. Birkenfeld, P., Haratz, N., Klein, G. and Sulitzeanu, D. (1990). Clin. Immunol. Immunopathol. 54, 14–25.PubMedCrossRefGoogle Scholar
  3. Cheeseman, S. H. (1988). Sem. Hematol. 25, 261–268.Google Scholar
  4. Dillner, J. and Kallin, B. (1988). In Advances in Cancer Research Vol. 50 (G. Klein and S. Weinhouse, eds.), pp. 95–158, Academic Press, San Diego.Google Scholar
  5. Faerber, I., Wutzler, P., Wohlrabe, P., Wolf, H., Hinderer, W. and Sonneborn, H.-H. (1993). J. Virol. Method. 42, 301–308.CrossRefGoogle Scholar
  6. Fox, R. I., Scott, S., Houghten, R., Whalley, A., Geltofsky, J., Vaughan, J. and Smith, R. (1987). J. Clin. Lab. Anal. 1, 140–145.CrossRefGoogle Scholar
  7. Geltofsky, J. E., Smith, R. S., Whalley, A. and Rhodes, G. (1987). J. Clin. Lab. Anal. 1, 153–162.CrossRefGoogle Scholar
  8. Gorgievski-Hrisoho, M., Hinderer, W., Nebel-Schickel, H., Horn, J., Vornhagen, R., Sonneborn, H.-H., Wolf, H. and Siegl, G. (1990). J. Clin. Microbiol. 28, 2305–2311.Google Scholar
  9. Henle, G., Henle, W. and Klein, G. (1971). Intl. J. Cancer 8, 272–282.CrossRefGoogle Scholar
  10. Henle, G., Lenette, E. T., Alspaugh, M. A. and Henle, W. (1979). tl 36, 415–422.Google Scholar
  11. Henle, W., Henle, G. andersson, J., Ernberg, J., Klein, G., Horwitz, C. A., Marklund, G., Rymo, L., Wellinder, C. and Straus, S. E. (1987). Proc. Natl. Acad. Sci. USA 84, 570–574.PubMedCrossRefGoogle Scholar
  12. Henle, W., Henle, G. and Horwitz, C. A. (1974). Hum. Pathol. 5, 551–556.PubMedCrossRefGoogle Scholar
  13. Hinderer, W., Nebel-Schickel, H., Sonneborn, H.-H., Motz, M., Kühbeck, R. and Wolf, H. (1988). J. Exptl. Cancer Res. 7, 132.Google Scholar
  14. Hinderer, W., Nebel-Schickel, H., Horn, J., Vornhagen, R., Sonneborn, H.-H., Gorgievski-Hrisoho, M., Siegl, G., Faerber, I., Wutzler, P. and Wolf, H. (1991). In Epstein-Barr Virus and Human Disease 1990 (D. V. Ablashi, A. T. Huang, J. S. Pagano, G. R. Pearson and C. S. Yang, eds.), pp. 123–125, Humana Press, Clifton.Google Scholar
  15. Linde, A., Kallin, B., Dillner, J. Andersson, J., Jägdahl, L., Lindvall, A. and Wahren, B. (1990)4. Infect. Dis. 161, 903–909.Google Scholar
  16. Middeldorp, J. M. and Meloen, R. H. (1988). J. Virol. Method. 21, 147–159.CrossRefGoogle Scholar
  17. Motz, M., Fan, J., Seibl, R., Jilg, W. and Wolf, H. (1986). Gene 42, 303–312.PubMedCrossRefGoogle Scholar
  18. Pearson, G. R. (1988). J. Virol. Method. 21, 97–104.CrossRefGoogle Scholar
  19. Pearson, G. R. and Luka, J. (1986). In The Epstein-Barr Virus: Recent Advances (M. A. Epstein and B. G. Achong, eds.), pp. 48–74, W. Heinemann, London.Google Scholar
  20. Reedman, B. M. and Klein, G. (1973). Intl. J. Cancer 11, 499–520.CrossRefGoogle Scholar
  21. Sumaya, C. V. (1989). J. Clin. Immunoassay 12, 168–174.Google Scholar
  22. Van Grunsven, W. M. J., Van Heerde, E. C., De Haard, H. J. W.,Spaan, W. J. M. and Middeldorp, J. M. (1993a). J. Virol. 67, 3908–3916.PubMedGoogle Scholar
  23. Van Grunsven, W. M. J., Nabbe, A. and Middeldorp, J. M. (1993b). J. Med. Virol. 40, 161–169.PubMedCrossRefGoogle Scholar
  24. Wolf, H., Motz, M., Kühbeck, R., Seibl, R., Bayliss, G. J., Modrow, S. and Fan, J. (1985). In Developements in Medical Virology Vol. 1: Epstein-Barr Virus and Associated Diseases (P. H. Levine, D. V. Ablashi and G. R. Pearson, eds.), pp. 485–494, M. Nijhoff Publishing, Boston.Google Scholar
  25. zur Hausen, H., Schulte-Holthausen, H., Klein, G., Henle, W., Henle, G., Clifford, P. and Santesson, L. (1970). Nature 288, 1056–1058.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • Walter Hinderer
    • 1
  • Günter Siegl
    • 2
  1. 1.BIOTEST AG, Research Dept.DreieichGermany
  2. 2.Institute for Clinical Microbiology and ImmunolologySt. GallenSwitzerland

Personalised recommendations